LivsMed has partnered with Sovato on telesurgery. Supply: LivsMed
LivsMed LLC final week stated it has accomplished an preliminary public providing, or IPO, on Korea’s KOSDAQ market. It raised about ₩135.9 billion ($94 million U.S.) at ₩55,000 per share, bringing its market capitalization to ₩1.4 trillion, or roughly $1 billion, making it a medical know-how “unicorn.”
The firm stated it can use the proceeds to construct an built-in manufacturing base, fund analysis and improvement, and strengthen associated administration methods to help international progress throughout its product portfolio.
“As we scale globally, we stay targeted on making superior surgical functionality extra accessible,” stated Jung Joo Lee, Ph.D., founder and CEO of LivsMed. “An innovation can’t be known as an innovation until it may well attain the lots.”
LivsMed develops methods for minimally invasive procedures, and collaborates with physicians worldwide to enhance affected person outcomes and broaden entry to superior surgical capabilities. The corporate is headquartered in Seoul and has a U.S. subsidiary in San Diego.
Roadmap contains robots for the U.S., laparoscopic devices
In July 2025, LivsMed demonstrated the capabilities of its STARK surgical robotic in an early feasibility wet-lab examine performed with telesurgery platform supplier Sovato. Within the demo, the surgeon console was positioned in Santa Barbara, Calif., whereas the robotic system was in Chicago, supporting long-distance connectivity.
The STARK robot-assisted surgical system is just not but permitted to be used and isn’t on the market within the U.S.
LivsMed additionally plans to broaden its portfolio of merchandise for minimally invasive surgical procedure. Launched in 2018, ArtiSential is a line of absolutely articulating handheld laparoscopic devices designed to supply wrist-like dexterity.
The corporate has expanded its platform with ArtiSeal, a 90-degree articulating vessel sealer that it stated allows multi-angle entry in confined anatomy.
LivsMed attracts international funding
LivsMed stated its IPO drew important curiosity from main home pension funds and establishments, in addition to giant international monetary establishments headquartered in New York and Boston. Throughout institutional e-book constructing, the corporate reported demand of roughly 231-to-1, with abroad participation representing 8.2% of the institutional demand, together with buyers from the U.S., the Center East, and Asia.
On its market debut, LivsMed shares opened greater than 10% above the providing worth, which it stated mirrored constructive preliminary market reception. Samsung Securities and Mirae Asset Securities served as joint lead underwriters.
The greenback equivalents offered above used an change price of ₩1,445 per $1 as of Dec. 24, 2025.
